Business Context and Reporting Period
This Form 8-K Current Report was filed by Silexion Therapeutics Corp on March 25, 2026. The registrant is incorporated in the Cayman Islands with principal executive offices in Ramat-Gan, Israel. The company is designated as an emerging growth company. Its ordinary shares (SLXN) and warrants (SLXNW) trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material event reported is the removal of a director:
- Item 5.02: On March 25, 2026, the Board of Directors removed Ilan Levin from his position as a member of the Board, effective immediately.
- The removal was executed via a unanimous written determination by all other Board members pursuant to Article 28.7 of the Company's Amended and Restated Articles of Association.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The report is limited to the notification of the director's departure.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following the removal of Ilan Levin.
- Review the Company's Amended and Restated Articles of Association, specifically Article 28.7, to understand the governance procedures for director removal.
- Check for any subsequent press releases or filings explaining the rationale behind the removal, as this 8-K does not disclose the reason.
- Confirm if the removal impacts any ongoing committee assignments or quorum requirements for the Board.